For Abeona Therapeutics Inc. (ABEO), the road to FDA approval for Zevaskyn was far from smooth. After facing an initial regulatory setback, the company achieved a breakthrough in April 2025, when Zevaskyn became the first and only FDA-approved cell-based gene therapy for recessive dystrophic epidermolysis bullosa.
Recessive dystrophic epidermolysis bullosa (RDEB) is caused by mutations in both copies of the COL7A1 gene that expresses Type VII collagen. The Type VII collagen is necessary to anchor the dermal and epidermal layers of the skin. People with RDEB have extremely fragile skin characterised by extensive blistering and severe wounds that often cover more than 30 percent of a patient's body surface, and in some cases up to 80 percent. RDEB wounds cause debilitating pain and systemic complications, impacting the length and quality of life. These wounds are difficult to heal, can remain open for years, and many that do close tend to reopen.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.